Results 31 to 40 of about 9,830 (184)

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

Frontiers in Endocrinology, 2021
ObjectivesGrowing evidence argues for a relationship between liver and bone metabolisms. Sclerostin is a secreted glycoprotein and could antagonize osteoblast-mediated bone formation.
Fangli Zhou, Fangli Zhou, Yan Wang, Yujue Li, Mengjia Tang, Shan Wan, Haoming Tian, Xiang Chen   +7 more
doaj   +1 more source

Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives

Journal of Orthopaedic Translation
Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases. Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone diseases in which therapeutic potential of sclerostin inhibition cannot be ignored.
Tao Xiaohui, Luyao Wang, Xin Yang, Hewen Jiang, Ning Zhang, Huarui Zhang, Dijie Li, Xiaofei Li, Yihao Zhang, Shenghang Wang, Chuanxin Zhong, Sifan Yu, Meishen Ren, Meiheng Sun, Nanxi Li, Tienan Chen, Yuan Ma, Fangfei Li, Jin Liu, Yuanyuan Yu, Hua Yue, Zhenlin Zhang, Ge Zhang   +22 more
doaj   +1 more source

The association of circulating sclerostin level with markers of bone metabolism in patients with thyroid dysfunction [PDF]

Journal of Medical Biochemistry, 2020
Background: The aim of this study was to compare serum sclerostin concentrations in patients with thyroid dysfunction with euthyroid control subjects and to assess the relationship between sclerostin and markers of bone metabolism (osteocalcin and beta ...
Mihaljević Olgica, Živančević-Simonović Snežana, Lučić-Tomić Aleksandra, Živković Irena, Minić Rajna, Mijatović-Teodorović Ljiljana, Jovanović Zorica, Anđelković Marija, Stanojević-Pirković Marijana   +8 more
doaj  

Sclerostin expression in skeletal sarcomas [PDF]

Human Pathology, 2016
Sclerostin (SOST) is an extracellular Wnt signaling antagonist which negatively regulates bone mass. Despite this, the expression and function of SOST in skeletal tumors remain poorly described. Here, we first describe the immunohistochemical staining pattern of SOST across benign and malignant skeletal tumors with bone or cartilage matrix (n=68 ...
Shen, Jia, Meyers, Carolyn A, Shrestha, Swati, Singh, Arun, LaChaud, Greg, Nguyen, Vi, Asatrian, Greg, Federman, Noah, Bernthal, Nicholas, Eilber, Fritz C, Dry, Sarah M, Ting, Kang, Soo, Chia, James, Aaron W   +13 more
openaire   +4 more sources

Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis

Toxins, 2019
Sclerostin is a well-known inhibitor of bone formation that acts on Wnt/β-catenin signaling. This manuscript considers the possible role of sclerostin in vascular calcification, a process that shares many similarities with physiological bone ...
Annelies De Maré, Stuart Maudsley, Abdelkrim Azmi, Jhana O. Hendrickx, Britt Opdebeeck, Ellen Neven, Patrick C D’Haese, Anja Verhulst   +7 more
doaj   +1 more source

Bone Sclerostin and Dickkopf-related protein-1 are positively correlated with bone mineral density, bone microarchitecture, and bone strength in postmenopausal osteoporosis

BMC Musculoskeletal Disorders, 2021
Background Wnt-catenin signaling antagonists sclerostin and dickkopf-related protein-1 (Dkk-1) inhibit bone formation and are involved in the pathogenesis of postmenopausal osteoporosis (PO). However, the association between sclerostin and Dkk-1 and bone
Jia Peng, Zhang Dong, Zhang Hui, Wang Aifei, Deng Lianfu, Xu Youjia   +5 more
doaj   +1 more source

The Effects of Sclerostin on the Immune System [PDF]

Current Osteoporosis Reports, 2020
We reviewed recent progress on the role of sclerostin (SOST) and its effects on the immune system in order to summarize the current state of knowledge in osteoimmunology, in regard to hematopoiesis, lymphopoiesis, and inflammation.Changes in sclerostin levels affect distinct niches within the bone marrow that support hematopoietic stem cells and B cell
Cristine Donham, Jennifer O. Manilay
openaire   +4 more sources

Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease

Frontiers in Endocrinology, 2022
Patients with Gaucher disease (GD) have progressive bone involvement that clinically presents with debilitating bone pain, structural bone changes, bone marrow infiltration (BMI), Erlenmeyer (EM) flask deformity, and osteoporosis. Pain is referred by the
Margarita M. Ivanova, Julia Dao, Neil Kasaci, Andrew Friedman, Lauren Noll, Ozlem Goker-Alpan   +5 more
doaj   +1 more source

Deep Learning Network‐Tailored Microenvironment Matching of 4D Bioprinting Bioactive Scaffolds for Bone Regeneration

Advanced Science, EarlyView.
A DLN dataset was built to analyze MABS composition versus in vitro/in vivo osteogenesis and angiogenesis. An MLP neural network, taking BG morphological parameters as input, extracts bioactive features from these datasets. A rabbit tibial defect model then validates 4D‐printed MABS for adaptability and bone regeneration in critical defects.
Xiongjie Liang, Yuechi Zhang, Weifeng Hu, Shiyan Lv, Fan Jia, Yan Zhang, Feng Wu, Changjiang Yang, Guanqi Zhen, Jinglong Yan, Xu Cui, Wei Zhao, Guanghua Chen   +12 more
wiley   +1 more source

Association of total and bioactive serum sclerostin levels with bone metabolism in type 2 diabetes mellitus

Journal of Clinical & Translational Endocrinology
Background: Sclerostin has been associated with decreased bone turnover in patients with type 2 diabetes mellitus (T2DM). The relationship with bone turnover markers (BTMs) and bone mineral density (BMD) remains unclear.
Cyril Traechslin, Lilian Sewing, Sandra Baumann, Leticia Grize, Janina Vavanikunnel, Marius Kraenzlin, Christoph Henzen, Christian Meier   +7 more
doaj   +1 more source